BioCryst Pharmaceuticals, Inc. - Common Stock (BCRX)
Healthcare › Biological Products, (No Diagnostic Substances)
Price History
Feb 9, 2026 — May 3, 2026Investment Snapshot
- P/E of 578.7 — elevated valuation multiple
- Piotroski F-Score 5/9 — moderate financial health
- Loss-making — negative ROE of -221.5%
BioCryst Pharmaceuticals, Inc. - Common Stock (BCRX) is a Healthcare company operating in Biological Products, (No Diagnostic Substances), listed on the NASDAQ , with a market capitalisation of $2.3 billion . Key value metrics: P/E ratio 578.7, Piotroski F-Score 5 out of 9 (moderate financial health) .
Value Score
Key Metrics
Revenue & Net Income
Financial Statements
| Metric | FY22 | FY23 | FY24 |
|---|---|---|---|
| Revenue | $X.XB | $X.XB | $X.XB |
| Gross Profit | $X.XB | $X.XB | $X.XB |
| Operating Income | $X.XB | $X.XB | $X.XB |
| Net Income | $X.XB | $X.XB | $X.XB |
| EBITDA | $X.XB | $X.XB | $X.XB |
| Total Assets | $X.XB | $X.XB | $X.XB |
| Total Liabilities | $X.XB | $X.XB | $X.XB |
BioCryst Pharmaceuticals, Inc. - Common Stock — Fundamental Analysis Summary
BioCryst Pharmaceuticals, Inc. - Common Stock (BCRX) trades at a trailing P/E of 578.7x — 2,199% above the Healthcare sector average of 25.2x.
On financial health, BCRX shows a moderate Piotroski F-Score of 5/9, and negative return on equity of -221.5% (sector average: -20.6%), and minimal leverage with a debt-to-equity ratio of 0.00.
StockPik's composite Value Score for BCRX is 50/100 — an above-average value rating. The score is built from ten fundamental signals: P/E, P/B, PEG ratio, P/S ratio, return on equity, gross margin, debt-to-equity, current ratio, dividend yield, and Piotroski F-Score.
BCRX shows earnings growing at 397%.